Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Pre-clinical studies have suggested that 5-HT(3) antagonists such as GR 68755 oppose mesocorticolimbic dopamine release, which may mediate the important effects of d-amphetamine on positive subjective mood, anorexia, and performance. Twenty-six healthy male volunteers received each of the following treatments in a double-blind, randomized, cross-over design separated by a period of four to seven days: (a) d-amphetamine (20mg orally); (b) placebo; (c) GR 68755 (2mg orally); and (d) GR 68755 plus d-amphetamine. Subjects completed subjective measures of mood, hunger, and satiety. Caloric and macronutrient intake were measured using a test meal. Performance and attention were assessed using standardized computerized tasks. GR 68755 enhanced accuracy on the computerized attention task but failed to reverse significantly any of the effects of d-amphetamine. These results suggest that at these doses GR 68755 pre-treatment does not significantly reduce the effects of d-amphetamine.


Journal article


Behav Pharmacol

Publication Date





216 - 227